Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate is AFREZZA, an ultra-rapid-acting inhaled insulin utilizing proprietary Technosphere formulation technology. The company also maintains a pipeline of cancer immunotherapy candidates (e.g., MKC1106-MT) and small molecule drugs.
Key Financial Metrics (Year Ended Dec 31, 2009)
| Metric | Value (in thousands) |
|---|---|
| Revenue | $0 |
| Net Loss | $(220,104) |
| Operating Expenses | $(209,778) |
| Research & Development | $(156,331) |
| General & Administrative | $(53,447) |
| Cash, Cash Equivalents & Marketable Securities | $32,494 |
| Working Capital | $8,813 |
| Total Debt (Senior Convertible Notes) | $112,765 |
| Related Party Loan (Principal Stockholder) | $165,000 |
| Accumulated Deficit | $(1,604,182) |
Material Changes vs. Prior Period
- Revenue: Remained at $0 for 2009, compared to $20,000 in 2008 (derived from a license agreement).
- Net Loss: Improved to $(220.1) million in 2009 from $(303.0) million in 2008, primarily due to a significant reduction in R&D expenses.
- R&D Expenses: Decreased by 38% to $156.3 million. This reduction was driven by the completion of pivotal AFREZZA trials in 2008 and a reduction in force in April 2009. However, this was partially offset by a $12.8 million loss on disposal of first-generation inhaler assets.
- Liquidity: Cash and marketable securities decreased from $46.5 million in 2008 to $32.5 million in 2009. However, the company increased borrowings under its related-party loan facility from $30.0 million to $165.0 million.
- Stockholders' Equity: Turned negative, resulting in a deficit of $(59.2) million, compared to positive equity of $86.7 million in 2008.
Guidance, Outlook, and Risks
Regulatory Status (AFREZZA)
On March 12, 2010, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for AFREZZA. The CRL did not require additional clinical trials but requested:
- Additional clinical data supporting clinical utility.
- Information on the comparability of the MedTone inhaler to the device used in pivotal trials.
- Updated safety data and labeling changes.
- Confirmation of a Risk Evaluation and Mitigation Strategy (REMS) to address respiratory risks.
The FDA inspection of a manufacturing facility was pending at the time of the filing. Management intends to request an End-of-Review meeting to resolve these issues. Commercial launch was not expected prior to 2011.
Liquidity and Capital Resources
Management believes existing capital resources, including the $185.0 million remaining available under the related-party loan facility, will fund operations into the first quarter of 2011. The company expects to require significant additional financing through equity/debt sales or strategic collaborations to continue development and commercialization. There is substantial doubt about the company's ability to continue as a going concern if additional funding is not secured.
Key Risks
- Regulatory Approval: No assurance that the FDA will approve AFREZZA or that the CRL issues can be resolved without further delay or cost.
- Capital Needs: History of operating losses and accumulated deficit of $1.6 billion; reliance on principal stockholder for liquidity.
- Commercialization: Lack of sales infrastructure; dependence on potential strategic partnerships for marketing and distribution.
- Intellectual Property: Potential infringement claims from third parties regarding pulmonary insulin delivery.
Investor Verification Checklist
- FDA Resolution: Verify the outcome of the End-of-Review meeting and whether the FDA accepts the company's response to the Complete Response Letter without requiring new clinical trials.
- Manufacturing Inspection: Confirm the status of the FDA inspection at the insulin supplier's facility and the company's Danbury facility.
- Capital Runway: Assess the company's ability to raise additional capital given the negative equity position and the approaching Q1 2011 liquidity horizon.
- Strategic Partnerships: Monitor progress in discussions with pharmaceutical partners for the commercialization of AFREZZA.
- Related Party Loan: Review the terms of the loan with The Mann Group LLC, specifically the prepayment rights and interest rate adjustments upon default.